EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Company’s $1.5bn To Last Into 2028
Executive Summary
Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.
You may also be interested in...
Revolution Picks Up Remains Of EQRx In All-Stock Deal
Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.
EQRx Raises White Flag On Its Low-Cost Drug Business Model
The company is backing out of the development of several clinical-stage assets and will cut 170 positions while it changes its business strategy.
Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.